Deal reached over FDA review of follow-on biotech drugs

A bipartisan group of senators plans to introduce a measure to give the FDA authority to approve follow-on versions of biotech drugs. The legislation from Democratic Sens. Edward Kennedy and Hillary Clinton and Republican Sens. Michael Enzi and Orrin Hatch allows for interchangeability of the follow-on biologic drugs but also gives biotechs four years of exclusivity before a generic maker can sell a biosimiliar and 12 years before a copycat version can go to market.

View Full Article in:

Bloomberg · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations